Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians
- 477 Downloads
Background Voriconazole is an antifungal drug essentially metabolized by cytochrome P450 (CYP2C19) isozyme. Plasma voriconazole levels exhibit wide inter-individual variability due to several factors like age, weight, food or drug interactions or CYP2C19 polymorphisms. Objective In the present study, we assessed the correlation of voriconazole levels with CYP2C19 genotype in patients on voriconazole therapy. Setting Biochemistry Department of a 480 inpatient bed tertiary care hospital in India. Methods Plasma voriconazole estimation was done in seventy-two patients on standard weight based voriconazole therapy by High Performance Liquid Chromatography (HPLC) while genotype assessment for the CYP2C19*2 and *3 was done by PCR–RFLP and *17 by ARMS-PCR. Statistical analysis and genotype-phenotype correlation was done by comparing the drug levels with the CYP2C19 genotype. Main outcome measure CYP2C19 polymorphisms influence voriconazole metabolism. Results A wide variability is seen in plasma levels with only 51 % attaining therapeutic levels. The allele frequency of *2, *3 and *17 variant were found to be 33.3, 0.7 and 18 % respectively. The drug levels in carriers of *2 allele (poor metabolizers) was twofold higher than that in extensive metabolizers. However, the influence of *2 allele was compromised in presence of *17 allele and patients had low voriconazole levels. In addition to the genotype, co-medication and clinical condition remarkably influenced voriconazole concentration. Conclusion Plasma voriconazole levels are influenced by CYP2C19 variants, drug interactions and clinical condition of the patient. Genotype assessment at initiation of therapy followed by drug monitoring would help optimizing therapeutic efficacy and minimizing toxicity.
KeywordsCYP2C19 Genotype-phenotype correlation India Therapeutic drug monitoring Voriconazole
We acknowledge National Health and Education Society (NHES) of P. D. Hinduja Hospital and Medical Research Centre for all their help.
No specific funding was obtained for the study.
Conflicts of interest
All authors declare that they have no conflict of interest.
- 1.VFEND® I.V. (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension [US physician prescribing information] New York (NY) Roerig Division of Pfizer Inc; revised 2008 Mar [cited 2008 Sep 3]. http://media.pfizer.com/files/products/uspi_vfend.pdf. Last Accessed 5 Dec 2013.
- 2.Briefing document for voriconazole (oral and intravenous formulations). Prepared for submission to US Food and Drug Administration, Food and Drugs Advisory Committee. Pfizer; 2001 Oct 4 [cited 2008 Sep 3]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf. Last Accessed 20 Jan 2014.
- 17.Guidance for the Industry: Bioanalytical Method Validation. Washington, DC: US Department of health and Human Services, FDA, CDER and CVM; 2001 BP.Google Scholar
- 28.Jeong Y, Tantry U, Kim I et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv. 2011;4(6):585–94. doi: 10.1161/circinterventions.111.962555.